- Business Wire•5 days ago
BioTime, Inc. , a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the closing of its previously announced underwritten public offering.
- Business Wire•5 days agoCORRECTING and REPLACING BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh
Please replace the release dated February 6, 2017, with the following corrected version due to multiple revisions.
- Business Wire•8 days ago
BioTime, Inc. , a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will be presenting at the BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York City on Tuesday, February 14, at 2:30 p.m.
BTX : Summary for BioTime, Inc. - Yahoo Finance
BioTime, Inc. (BTX)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Day's Range||2.93 - 3.04|
|52 Week Range||2.21 - 4.01|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||11.29|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|